TABLE OF CONTENTS
1 INTRODUCTION 63
1.1 OBJECTIVES OF THE STUDY 63
1.2 MARKET DEFINITION 63
1.3 OVERVIEW OF EUROPE PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET 63
1.4 CURRENCY AND PRICING 65
1.5 LIMITATIONS 66
1.6 MARKETS COVERED 66
2 MARKET SEGMENTATION 70
2.1 MARKETS COVERED 70
2.2 GEOGRAPHICAL SCOPE 71
2.3 YEARS CONSIDERED FOR THE STUDY 72
2.4 DBMR TRIPOD DATA VALIDATION MODEL 73
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 76
2.6 MULTIVARIATE MODELLING 77
2.7 MARKET APPLICATION COVERAGE GRID 78
2.8 SOURCE LIFELINE CURVE 78
2.9 DBMR MARKET POSITION GRID 80
2.10 VENDOR SHARE ANALYSIS 81
2.11 SECONDARY SOURCES 82
2.12 ASSUMPTIONS 82
3 EXECUTIVE SUMMARY 83
3.1 PESTEL ANALYSIS 87
3.2 PORTER'S FIVE FORCES MODEL 88
3.3 INDUSTRIAL INSIGHTS: 89
3.4 PIPELINE ANALYSIS FOR EUROPE PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET 91
3.5 EPIDEMIOLOGY 92
4 EUROPE PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, REGULATIONS 93
4.1 UNITED STATES (U.S.) 93
4.1.1 ROLE OF FDA 93
4.1.2 ROLE OF CDC AND HCFA 93
4.2 EUROPEAN UNION (EU) 94
4.3 FRANCE 94
4.4 AUSTRALIA 94
4.5 SOUTH KOREA 94
5 MARKET OVERVIEW 95
5.1 DRIVERS 97
5.1.1 INCREASE IN THE NUMBER OF PATIENTS SUFFERING FROM PSYCHIATRIC AND DEPRESSION DISORDER 97
5.1.2 RISE IN HEALTHCARE EXPENDITURE 97
5.1.3 RISE IN DEMAND FOR PERSONALIZED AND PRECISION MEDICINE 98
5.2 RESTRAINTS 98
5.2.1 LACK OF SKILLED MEDICAL AND GENOMIC EXPERT 98
5.2.2 LACK OF STRONG CLINICAL EVIDENCE 99
5.2.3 HIGH COST ASSOCIATED WITH THE DIAGNOSIS 99
5.3 OPPORTUNITIES 99
5.3.1 RISING ADVANCEMENTS IN TECHNOLOGY 99
5.3.2 INCREASING NUMBER OF KEY PLAYERS IN MARKET 100
5.4 CHALLENGES 100
5.4.1 STRICT GOVERNMENT REGULATION ON NEW PRODUCTS AND INSTRUMENTS APPROVAL 100
5.4.2 DEARTH OF SKILLED PERSONNEL 101
6 EUROPE PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE 102
6.1 OVERVIEW 103
6.2 ANXIETY 106
6.3 DEPRESSION 106
6.4 MOOD DISORDERS 107
6.5 BIPOLAR DISORDERS 108
6.6 EATING DISORDERS 109
6.7 PSYCHOTIC DISORDERS 109
7 EUROPE PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT 111
7.1 OVERVIEW 112
7.2 CONSUMABLES 115
7.2.1 WHOLE GENOME SEQUENCING KITS 116
7.2.2 CHROMOSOMAL ARRAY BASED KITS 116
7.3 INSTRUMENTS 117
7.4 SOFTWARE AND SERVICES 117
8 EUROPE PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE 119
8.1 OVERVIEW 120
8.2 WHOLE GENOME SEQUENCING 123
8.2.1 EXOME SEQUENCING 124
8.2.1.1 SNP 125
8.2.1.2 CNV 125
8.2.1.3 RARE PTV MUTATION 125
8.2.1.4 ULTRA PTV MUTATION 125
8.2.1.5 OTHERS 125
8.2.2 KARYOTYPE 125
8.2.2.1 SNP 126
8.2.2.2 CNV 126
8.2.2.3 RARE PTV MUTATION 126
8.2.2.4 ULTRA PTV MUTATION 126
8.2.2.5 OTHERS 126
8.2.3 LOW COVERAGE WGS 126
8.2.3.1 SNP 127
8.2.3.2 CNV 127
8.2.3.3 RARE PTV MUTATION 127
8.2.3.4 ULTRA PTV MUTATION 127
8.2.3.5 OTHERS 127
8.2.4 DEEP COVERAGE WGS 127
8.2.4.1 SNP 128
8.2.4.2 CNV 128
8.2.4.3 RARE PTV MUTATION 128
8.2.4.4 ULTRA PTV MUTATION 128
8.2.4.5 OTHERS 128
8.2.5 MICROARRAY 128
8.2.5.1 SNP 129
8.2.5.2 CNV 129
8.2.5.3 RARE PTV MUTATION 129
8.2.5.4 ULTRA PTV MUTATION 129
8.2.5.5 OTHERS 129
8.2.6 OTHERS 129
8.3 CHROMOSOMAL ARRAY BASED TESTS 129
8.3.1 MICRODELETIONS 130
8.3.2 MICRO DUPLICATIONS 130
9 EUROPE PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENE TYPE 131
9.1 OVERVIEW 132
9.2 CYP2C19 135
9.3 CYP2C9 AND VKORC1 135
9.4 CYP2D6 136
9.5 HLA-B 137
9.6 HTR2A/C 137
9.7 HLA-A 138
9.8 CYP3A4 139
9.9 SLC6A4 139
9.10 MTHFR 140
9.11 COMT 141
9.12 OTHERS 141
10 EUROPE PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PATIENT TYPE 143
10.1 OVERVIEW 144
10.2 ADULT 147
10.3 GERIATRIC 147
10.4 CHILD 148
11 EUROPE PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET , BY END USER 149
11.1 OVERVIEW 150
11.2 HOSPITAL AND CLINICS 153
11.2.1 DRUG EFFECTIVENESS 154
11.2.2 SIDE EFFECTS 154
11.2.3 DOSAGE 154
11.3 DIAGNOSTICS LABORATORIES 154
11.3.1 DRUG EFFECTIVENESS 155
11.3.2 SIDE EFFECTS 155
11.3.3 DOSAGE 155
11.4 ACADEMIC AND RESEARCH INSTITUTES 155
11.4.1 DRUG EFFECTIVENESS 156
11.4.2 SIDE EFFECTS 156
11.4.3 DOSAGE 156
11.5 OTHERS 156
12 EUROPE PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL 158
12.1 OVERVIEW 159
12.2 DIRECT TENDER 162
12.3 THIRD PARTY DISTRIBUTION 162
12.4 HOSPITAL PHARMACY 163
12.5 OTHERS 163
13 EUROPE PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION 165
13.1 EUROPE 166
13.1.1 GERMANY 178
13.1.2 FRANCE 185
13.1.3 U.K. 192
13.1.4 ITALY 199
13.1.5 RUSSIA 206
13.1.6 SPAIN 213
13.1.7 TURKEY 220
13.1.8 NETHERLANDS 227
13.1.9 SWITZERLAND 234
13.1.10 POLAND 241
13.1.11 HUNGARY 248
13.1.12 AUSTRIA 255
13.1.13 NORWAY 262
13.1.14 IRELAND 269
13.1.15 LITHUANIA 276
13.1.16 REST OF EUROPE 283
14 EUROPE PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET: COMPANY LANDSCAPE 284
14.1 COMPANY SHARE ANALYSIS: EUROPE 284
15 SWOT ANALYSIS 285
16 COMPANY PROFILE 286
16.1 THERMO FISHER SCIENTIFIC INC. 286
16.1.1 COMPANY SNAPSHOT 286
16.1.2 RECENT FINANCIALS 286
16.1.3 COMPANY SHARE ANALYSIS 287
16.1.4 PRODUCT PORTFOLIO 287
16.1.5 RECENT DEVELOPMENT 288
16.2 ILLUMINA, INC. 289
16.2.1 COMPANY SNAPSHOT 289
16.2.2 REVENUE ANALYSIS 289
16.2.3 COMPANY SHARE ANALYSIS 290
16.2.4 PRODUCT PORTFOLIO 290
16.2.5 RECENT DEVELOPMENTS 291
16.3 MYRIAD GENETICS, INC. 293
16.3.1 COMPANY SNAPSHOT 293
16.3.2 COMPANY SHARE ANALYSIS 293
16.3.3 PRODUCT PORTFOLIO 294
16.3.4 RECENT DEVELOPMENT 294
16.4 SONIC HEALTHCARE LIMITED 295
16.4.1 COMPANY SNAPSHOT 295
16.4.2 REVENUE ANALYSIS 295
16.4.3 COMPANY SHARE ANALYSIS 296
16.4.4 PRODUCT PORTFOLIO 296
16.4.5 RECENT DEVELOPMENTS 296
16.5 QIAGEN 297
16.5.1 COMPANY SNAPSHOT 297
16.5.2 RECENT FINANCIALS 297
16.5.3 COMPANY SHARE ANALYSIS 298
16.5.4 PRODUCT PORTFOLIO 298
16.5.5 RECENT DEVELOPMENTS 299
16.6 EUROFINS SCIENTIFIC 300
16.6.1 COMPANY SNAPSHOT 300
16.6.2 REVENUE ANALYSIS 300
16.6.3 PRODUCT PORTFOLIO 301
16.6.4 RECENT DEVELOPMENT 301
16.7 AB-BIOTICS, S.A. 302
16.7.1 COMPANY SNAPSHOT 302
16.7.2 PRODUCT PORTFOLIO 302
16.7.3 RECENT DEVELOPMENTS 302
16.8 BIOGENIQ INC. 304
16.8.1 COMPANY SNAPSHOT 304
16.8.2 PRODUCT PORTFOLIO 304
16.8.3 RECENT DEVELOPMENT 304
16.9 CASTLE BIOSCIENCE, INC. 305
16.9.1 COMPANY SNAPSHOT 305
16.9.2 REVENUE ANALYSIS 305
16.9.3 PRODUCT PORTFOLIO 306
16.9.4 RECENT DEVELOPMENT 306
16.10 CNSDOSE 307
16.10.1 COMPANY SNAPSHOT 307
16.10.2 PRODUCT PORTFOLIO 307
16.10.3 RECENT DEVELOPMENT 307
16.11 COLOR HEALTH, INC. 308
16.11.1 COMPANY SNAPSHOT 308
16.11.2 PRODUCT PORTFOLIO 308
16.11.3 RECENT DEVELOPMENTS 309
16.12 CORIELL LIFE SCIENCES 310
16.12.1 COMPANY SNAPSHOT 310
16.12.2 PRODUCT PORTFOLIO 310
16.12.3 RECENT DEVELOPMENTS 310
16.13 DYNAMIC DNA LABORATORIES 313
16.13.1 COMPANY SNAPSHOT 313
16.13.2 PRODUCT PORTFOLIO 313
16.13.3 RECENT DEVELOPMENTS 313
16.14 GENELEX (SUBSIADIARY OF INVITAE CORPORATION.) 315
16.14.1 COMPANY SNAPSHOT 315
16.14.2 REVENUE ANALYSIS 315
16.14.3 PRODUCT PORTFOLIO 316
16.14.4 RECENT DEVELOPMENT 316
16.15 GENEWIZ (PART OF AZENTA LIFE SCIENCES) 317
16.15.1 COMPANY SNAPSHOT 317
16.15.2 REVENUE ANALYSIS 317
16.15.3 PRODUCT PORTFOLIO 318
16.15.4 RECENT DEVELOPMENTS 318
16.16 GENOMIND, INC. 319
16.16.1 COMPANY SNAPSHOT 319
16.16.2 PRODUCT PORTFOLIO 319
16.16.3 RECENT DEVELOPMENTS 319
16.17 GENXYS 321
16.17.1 COMPANY SNAPSHOT 321
16.17.2 PRODUCT PORTFOLIO 321
16.17.3 RECENT DEVELOPMENTS 321
16.18 HEALTHSPEK 323
16.18.1 COMPANY SNAPSHOT 323
16.18.2 PRODUCT PORTFOLIO 323
16.18.3 RECENT DEVELOPMENTS 323
16.19 HUDSONALPHA 324
16.19.1 COMPANY SNAPSHOT 324
16.19.2 PRODUCT PORTFOLIO 324
16.19.3 RECENT DEVELOPMENT 324

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.